Single-Use unit and Process Analytical Infrared Spectroscopy

Projektinformationen

SUPAIR Spectroscopy

ID Finanzhilfevereinbarung: 954732

DOI

10.3030/954732

Projekt abgeschlossen

EK-Unterschriftsdatum 30 April 2020

Startdatum 1 Mai 2020

Enddatum 30 April 2022

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 1 880 327,50

EU-Beitrag

€ 1 316 229,25

Koordiniert durch

IRUBIS GMBH
Germany

Periodic Reporting for period 2 - SUPAIR Spectroscopy (Single-Use unit and Process Analytical Infrared Spectroscopy)

Berichtszeitraum: 2021-02-01 bis 2022-04-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

IRUBIS GmbH developed within the project a novel analytical device that enables continuous real-time monitoring of bioprocesses using mid-infrared spectroscopy with a single use flow cell. Its market is in process development and manufacturing of biological drugs, such as vaccines. The objective of ‘SUPAIR Spectroscopy’ project was to develop the mid-infrared spectroscopy system in line with the biopharma user requirements and to lay the groundwork for successful market commercialization. The validation and feedback by biopharma companies was essential for the project. Additionally, their feedback as well as the promotion of the results laid the foundation for the commercialization strategy.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

During the first 9 month of the action the hardware and software were developed: a monitoring and control solution, including an algorithm that can monitor glucose and lactate, without extensive calibration model building and a control feature to keep the glucose concentration at a constant level. During the second period ‘Monipa’ was validated, and the manufacturing of the analytical device was adapted based on the feedback from biopharma users to achieve a suitable process analytical technology for the biopharma industry. In parallel a business innovation plan and commercialization plan has been developed and dissemination as well as exploitation activities conducted.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

We see the future impact of ‘Monipa’ on the one hand by enabling an increase of the product gain and to achieve higher quality of biopharmaceutical drugs by a continuous control of the nutrient parameter in the bioprocess. On the other hand, a continuous control and real-time monitoring of nutrients and metabolites in the bioprocess leads to a higher process know-how and decrease the time for process development. In a consequence the new technology brings biopharmaceuticals faster to the patient.

Monipa, real-time monitoring of bioprocesses